Metastatic Colorectal Cancer Pipeline Insights Report 2024 (Updated) | include Mirati Therapeutics, Shanghai Zhangjiang Biotechnology Limited Company, Genor Biopharma Co., Ltd., and others.

DelveInsight's, "Metastatic Colorectal Cancer Pipeline Insight 2024" report provides comprehensive insights about 130+ companies and 140+ pipeline drugs in the Metastatic Colorectal Cancer pipeline landscape. It covers the Metastatic Colorectal Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Metastatic Colorectal Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Metastatic Colorectal Cancer Pipeline Report
• DelveInsight's Metastatic Colorectal Cancer pipeline report depicts a robust space with 130+ active players working to develop 140+ pipeline therapies for Metastatic Colorectal Cancer treatment.
• The leading companies working in the Metastatic Colorectal Cancer Market include Mirati Therapeutics, Shanghai Zhangjiang Biotechnology Limited Company, Genor Biopharma Co., Ltd., Menarini Group, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Arcus Biosciences, Inc., SFJ Pharmaceuticals, Merck Serono, Sumitomo Pharma Co., Ltd., Immunovative Therapies, Ltd., Cardiff Oncology, Symphogen A/S, Genentech, Qilu Pharmaceutical Co., Ltd., Henlix Biotech, Scandion Oncology A/S, Aadi Bioscience, Inc., Novartis, Roche, Boehringer Ingelheim, Isofol Medical, Treos Bio, Suzhou Suncadia Biopharmaceuticals Co., Ltd., Elevar Therapeutics, Shanghai Henlius Biotech, and others.
• Promising Metastatic Colorectal Cancer Pipeline Therapies in the various stages of development include ZN-c3, Encorafenib, Cetuximab, CMAB009 plus Irinotecan, Trifluridin/Tipiracil, AB680, Etrumadenant, Zimberelimab, and others.
• April 2024: Bristol-Myers Squibb- A Phase 3 Randomized Clinical Trial of Nivolumab Alone, Nivolumab in Combination With Ipilimumab, or Investigator's Choice Chemotherapy in Participants With Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Metastatic Colorectal Cancer. The main purpose of this study is to compare the clinical benefit, as measured by Progression-Free Survival (PFS), Objective Response Rate (ORR), and Overall Survival (OS), achieved by nivolumab in combination with ipilimumab or by nivolumab monotherapy in participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) metastatic colorectal cancer (mCRC). This study will also compare nivolumab plus ipilimumab combination vs chemotherapy for treatment of MSI-H/dMMR mCRC participants.
• April 2024:- Cardiff Oncology- A Phase 2, Randomized, Open-label Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-line Treatment of Metastatic Colorectal Cancer in Patients With a KRAS or NRAS Mutation. The purpose of this study is to assess 2 different doses of onvansertib to select the lowest dose that is maximally effective, and to assess the safety, efficacy, pharmacokinetics, and pharmacodynamics of onvansertib in combination with FOLFIRI + bevacizumab or FOLFOX + bevacizumab in patients with KRAS or NRAS-mutated metastatic colorectal cancer (CRC) in the first-line setting.
• April 2024:- Bayer- Real-world Sequence of Systemic Therapies and Outcomes in Patients With Metastatic Colorectal Cancer Receiving 3rd and 4th Line of Treatment. The main purpose of this study is to learn more about the effects of treatment in people with mCRC who have already received regorafenib and TAS, with or without bevacizumab, one after the other (also called sequential treatment) in a different order.

Request a sample and discover the recent advances in Metastatic Colorectal Cancer Treatment Drugs @ Metastatic Colorectal Cancer Pipeline Report- https://www.delveinsight.com/sample-request/metastatic-colorectal-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

In the Metastatic Colorectal Cancer pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Metastatic Colorectal Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Metastatic Colorectal Cancer Overview
Cancer cells may break away from a tumor in the colon and spread to other parts of the body through the bloodstream or lymphatic system. These cells may settle and form new tumors on a different organ. Even though the cancer has spread to a new organ, it is still named after the part of the body where it originally started.

Find out more about Metastatic Colorectal Cancer Therapeutics Assessment @ Metastatic Colorectal Cancer Preclinical and Discovery Stage Products- https://www.delveinsight.com/sample-request/metastatic-colorectal-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Metastatic Colorectal Cancer Emerging Drugs Profile
• Adagrasib (MRTX849): Mirati Therapeutics
• QL-1203: Qilu Pharmaceutical
• ZN-c3: Zentalis Pharmaceuticals

Metastatic Colorectal Cancer Pipeline Therapeutics Assessment
There are approx. 130+ key companies which are developing the Metastatic Colorectal Cancer pipeline therapies. The Metastatic Colorectal Cancer companies which have their Metastatic colorectal cancer drug candidates in the most advanced stage, i.e. phase III include, Mirati Therapeutics.

DelveInsight's Metastatic Colorectal Cancer Pipeline Report covers around 140+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Metastatic colorectal cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.

Metastatic Colorectal Cancer Pipeline Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Learn more about the emerging Metastatic Colorectal Cancer Pipeline Therapies @ Metastatic Colorectal Cancer Clinical Trials Assessment- https://www.delveinsight.com/sample-request/metastatic-colorectal-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Metastatic Colorectal Cancer Pipeline Report
• Coverage- Global
• Metastatic Colorectal Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Metastatic Colorectal Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Metastatic Colorectal Cancer Companies- Mirati Therapeutics, Shanghai Zhangjiang Biotechnology Limited Company, Genor Biopharma Co., Ltd., Menarini Group, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Arcus Biosciences, Inc., SFJ Pharmaceuticals, Merck Serono, Sumitomo Pharma Co., Ltd., Immunovative Therapies, Ltd., Cardiff Oncology, Symphogen A/S, Genentech, Qilu Pharmaceutical Co., Ltd., Henlix Biotech, Scandion Oncology A/S, Aadi Bioscience, Inc., Novartis, Roche, Boehringer Ingelheim, Isofol Medical, Treos Bio, Suzhou Suncadia Biopharmaceuticals Co., Ltd., Elevar Therapeutics, Shanghai Henlius Biotech, and others.
• Metastatic Colorectal Cancer Pipeline Therapies- ZN-c3, Encorafenib, Cetuximab, CMAB009 plus Irinotecan, Trifluridin/Tipiracil, AB680, Etrumadenant, Zimberelimab, and others.

Dive deep into rich insights for new drugs for Metastatic Colorectal Cancer Treatment, Visit @ Metastatic Colorectal Cancer Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/metastatic-colorectal-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Metastatic colorectal cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Metastatic colorectal cancer - DelveInsight's Analytical Perspective
7. In-depth Commercial Assessment
8. Metastatic colorectal cancer Collaboration Deals
9. Late Stage Products (Phase III)
10. MRTX849: Mirati Therapeutics
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase II)
13. AK-112: Akeso Biopharma
14. Drug profiles in the detailed report…..
15. Early Stage Products (Phase I)
16. SY 5609: Syros Pharmaceuticals
17. Drug profiles in the detailed report…..
18. Preclinical and Discovery Stage Products
19. Drug name: Company name
20. Drug profiles in the detailed report…..
21. Inactive Products
22. Metastatic colorectal cancer Key Companies
23. Metastatic colorectal cancer Key Products
24. Metastatic colorectal cancer- Unmet Needs
25. Metastatic colorectal cancer- Market Drivers and Barriers
26. Metastatic colorectal cancer- Future Perspectives and Conclusion
27. Metastatic colorectal cancer Analyst Views
28. Metastatic colorectal cancer Key Companies
29. Appendix

For further information on the Metastatic Colorectal Cancer Pipeline therapeutics, reach out to Metastatic Colorectal Cancer Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/metastatic-colorectal-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

List of Important Links-

http://demo.advised360.com/read-blog/154799
https://thehealthbridges.com/read-blog/19127
https://app.talkshoe.com/user/joneswilliam/about#google_vignette
https://www.vaca-ps.org/blogs/142022/The-Evolving-Landscape-of-Healthcare-Business-Consulting-Services
https://www.anobii.com/en/01d38d0b9694756e64/profile/activity
https://myanimelist.net/profile/dennydonesgerman
https://forum.pivx.org/threads/healthcare-business-consulting-services-navigating-complexity-in-modern-healthcare.2035/
https://pubhtml5.com/homepage/npvs/
https://b31.org.uk/author/anniesmith9/
https://fairygodboss.com/users/profile/Ix-vMa09gj/Annie-Smith
https://forum.completefrance.com/index.php?/topic/71194-key-areas-of-focus-in-healthcare-consulting-services/
https://educatorpages.com/site/kelleadvin/pages/blog?
https://offgridworld.com/author/anniejones9/
https://www.openhumans.org/member/me/
https://findpenguins.com/5zphebtv0zouo
http://jobs.emiogp.com/author/williamsmith9/
https://www.shippingexplorer.net/en/user/williamsmith9/88249
https://wakelet.com/@DennyDones813
https://startupxplore.com/en/person/denny-dones
https://www.nfpjobs.com.au/employers/1939365-delveinsight
https://community.hodinkee.com/members/dennydoness
https://jobs.mikeroweworks.org/employers/1930150-delveinsight
https://www.social-vape.com/read-blog/132516
https://codex.core77.com/users/dennydones9
https://www.newjerseyhunter.com/members/dennydones1.84566/#about
https://au.blurb.com/user/dennydones9?profile_preview=true
https://trabajo.merca20.com/author/kelleadvin/
https://www.atlasobscura.com/users/dennydones1
https://www.mixcloud.com/dennydones1/
https://www.designspiration.com/ybhardwaj/

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website:- https://www.delveinsight.com/

This release was published on openPR.